FDA approves first biosimilar for MS
2023-08-25
上市批准引进/卖出
Sandoz announced this week that it has received FDA approval for Tyruko, now the first biosimilar greenlighted to treat relapsing forms of multiple sclerosis (MS), offering treatment for all indications covered by the reference medicine.
The reference drug, Tysabri, was initially developed by Biogen. Tyruko shares the same intravenous dosage form, administration route, dosing regimen, and presentation as the reference medicine. Back in 2019, SandozSandoz and Polpharma Biologics entered a worldwide commercialization agreement for the biosimilar. Under this arrangement, Polpharma handled development, manufacturing and supply, while SandozSandoz was put in charge of marketing and distribution.
Tyruko, like Tysabri, will carry a boxed warning due to the higher risk of a severe brain infection called progressive multifocal leukoencephalopathy (PML). Factors like anti-JCV antibodies, extended therapy, and prior immunosuppressant use increase PML risk.
The FDA granted SandozSandoz approval based on data encompassing analytical, functional, and clinical effectiveness, covering various relapsing forms of MS. This includes clinically isolated syndrome, which involves the first MS symptom occurrence; relapsing-remitting disease, characterized by alternating symptom episodes and stability phases; and active secondary progressive disease, where gradual disability worsening and ongoing relapses follow an initial relapsing-remitting pattern.
MS is a chronic autoimmune disorder affecting the central nervous system, causing communication disruptions between the brain and body. It's a prevalent cause of neurological disability in young adults, occurring more in women. Typical MS involves relapses with deteriorating function and new symptoms, followed by remission. However, over time, incomplete recovery can result in a gradual decline in function and heightened disability.
Tyruko and reference drug Tysabri are also indicated for the treatment of moderately to severely active Crohn’s Disease showing inflammation evidence, and who haven't adequately responded to, or can't tolerate, standard CD treatments and TNF-α inhibitorsTNF-α inhibitors.
SandozSandoz, Novartis’ generics business, is slated to become Europe's largest generics company by sales. If all goes well during an upcoming meeting of its shareholders, Novartis says the spin-off — which will separate Sandoz into a new, publicly traded standalone company headquartered in Switzerland — will occur on or around October 4, 2023.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。